DISSOLUTION ENHANCEMENT OF POORLY WATER-SOLUBLE DRUG BY CYCLODEXTRINS INCLUSION COMPLEXATION
Objective: Solubility of a drug is an important property that mainly influences the extent of oral bioavailability. Enhancement of oral bioavailability of poorly water-soluble drugs is the most challenging aspects of drug development. It is very important to find appropriate formulation approaches to improve the aqueous solubility and bioavailability of poorly aqueous soluble drugs. Ezetimibe is a new lipid lowering agent in the management of hypercholesterolemia. The drug is water-insoluble, lipophilic, and highly permeable according to the pharmaceutical classification system. Therefore, the bioavailability of ezetimibe may be improved by increasing its solubility.
Methods: In present work solubility of ezetimibe was increased with inclusion complexes by a different technique like physical mixture, co-grinding and modified kneading method. The physical properties of the prepared inclusion complex of ezetimibe were characterised by Differential scanning calorimetry (DSC), X-ray diffraction spectroscopy (XRD), Fourier transform infra-red spectroscopy (FTIR) and in vitro dissolution studies.
Results: From the dissolution studies of ezetimibe with HP-Î²-cyclodextrin(1:1 and 1:2), we conclude that the prepared complexes of ezetimibe with HP-Î²-cyclodextrin (1:2) by modified kneading method showed higher release i.e. 88.35% in 60 min. than in (1:1) 76.75% in 60 min. So, ezetimibe with HP-Î²-cyclodextrin (1:2) inclusion complex was used to formulate tablet by direct compression method.
Conclusion: From the dissolution data of formulated tablets was observed that drug release was more in tablet dosage form as compared to plain ezetimibe and especially formulation in a ratio of 1:2 was found the promising result. Also from one-month stability data shows no significant change compared to the initial result.
Keywords: Ezetimibe, Cyclodextrin complex, Solubility enhancement, HP-Î²-cyclodextrin
2. Von Heek M, Farley C, Compton D. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pham 2001;134:409-17.
3. USP-NF. Table/Description and Solubility. Official Compendia Standards 2006;29:3191.
4. Loftsson T. Cyclodextrins and the biopharmaceutics classification system of Drugs. J Inclusion Phenom Macrocyclic Chem 2002;44:63-7.
5. Irie T, Uekama U. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. Am J Pharmacol Sci 1997;86:147â€“62.
6. Uekema K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998;98:2045â€76.
7. Loftsson T, HreinsdÃ³ttir D, MÃ¡sson M. Evaluation of cyclodextrin solubilization of drugs. In J Pharm 2005;302:18-28.
8. Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum 1965;4:117-22.
9. Botella S, Castillo B, Martyn A. Cyclodetrin properties and applications of inclusion complex formation. Ars Pharm 1995;36:187-98.
10. Uekama K, Hirayama F. Methods of investigating and preparing inclusion compounds. Cyclodextrins and Their Industrial Uses. Paris, France: Editions de SantÃ©; 1987. p. 131â€72.
11. Duchene D, Wouessidjewe D. Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, part I. Pharm Technol 1990;14:26â€34.
12. Srikanth M, Muralimohan G, Sriniwasrao N, Balaji S, Ramanamurthy K. Dissolution rate enhancement of poorly soluble bicalutamide using Beta-Cyclodextrin inclusion complex. Int J Pharm Pharm Sci 2010;2:191-8.
13. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2005;50:47â€60.
14. Kinoshita M, Kazuhiko B, Atushi N, Kanoo Y. Improvement of solubility and oral bioavailability of a poorly water-soluble drug. J Pharm Sci 2002;91:362â€70.
15. ICH, Q2R1 validation of analytic procedures: Text and methodology. International Conference on Harmonization, Geneva; 1994.
16. Khaled A, Asiri A, El-Sayed M. In vivo evaluation of hydrochlorothiazide liquid-solid tablets in beagle dogs. Int J Pharm 2001;222:1-6.
17. Simonella P, Meshalim M, Abd El-Gawad H, Abdel-Aleem M, Gabr E. Effect of some polymers on the physicochemical and dissolution properties of hydrochlorothiazide. Drug Dev Ind Pharm 1994;20:2741-52.
18. Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G. Specific permeability modulation of the intestinal paracellular pathway by chitosan-poly (isobutyl cyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm 2008;69:436-44.
19. Szetli J. Medicinal applications of cyclodextrins. Med Res Rev 1994;14:353â€86.
20. Alonsoa F, GonzÃ¡lezc R, Bernad-Bernadc J. Two novel ternary albendazoleâ€“Î² cyclodextrinâ€“polymer systems: dissolution, bioavailability and efficacy against Taenia crassiceps cysts. J Acta Tropica 2010;113:56â€“60.
21. Sakhare S, Yadav A, Jadhav P. Design,development and characterization of mucoadhesive gastrospheres of carvedilol. Int J Appl Pharm 2016;8:37-42.
22. Srikanth M, Muralimohan G, Sriniwasrao N, Balaji S, Ramanamurthy K. Dissolution rate enhancement of poorly soluble bicalutamide using Beta-Cyclodextrin inclusion complex. Int J Pharm Pharm Sci 2010;2:191-8.
23. Shriram P, Prashant M, Swapnil D, Arumugam K. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-preparation and in-vitro and in vivo evaluation. Eur J Pharm Sci 2010;41:440â€“51.